Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 514 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Boost Plus Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59

NCT03497845
View directory record Official record
Conditions
Influenza A Virus, H5N1 Subtype
Interventions
VN, IN, dk/BANG, gf/WA, bhg/QL, AS03 adjuvant, MF59 adjuvant
Biological
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years to 49 Years
Enrollment
720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
6
States / cities
San Diego, California • Peoria, Illinois • Lenexa, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 21, 2026, 10:24 PM EDT
Recruiting Phase 2 Interventional

Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma

NCT07497607
View directory record Official record
Conditions
Oropharyngeal Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions
Cisplatin, Radiotherapy
Drug · Radiation
Lead sponsor
Sara Medek
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 21, 2026, 10:24 PM EDT
Recruiting Not applicable Interventional

Nutrition Optimization and Community Upliftment for Postpartum Recovery

NCT06445530
View directory record Official record
Conditions
Obesity, Maternal, Gestational Diabetes
Interventions
MFeast ENHANCED, MFeast Usual Care
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 21, 2026, 10:24 PM EDT
Active, not recruiting Not applicable Interventional

Preoperative Irradiation for Stage I Breast Cancer

NCT05464667
View directory record Official record
Conditions
Breast Cancer
Interventions
Radiation Therapy (RT)
Radiation
Lead sponsor
Parul Barry
Other
Eligibility
50 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 21, 2026, 10:24 PM EDT
Suspended Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial to Evaluate the Safety and Immunogenicity of Glycan-trimmed HIV-1 Nanoparticle Vaccine (UVAX-1107), Followed by Homologous or Wild-type HIV-1 Nanoparticle Vaccine (UVAX-1197) Boost, Each Adjuvanted With 3M-052-AF + Alum in Adult Participants Without HIV

NCT06905275
View directory record Official record
Conditions
HIV-1-infection
Interventions
3M-052-AF + Alum, UVAX-1107, UVAX-1197
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
4
States / cities
Birmingham, Alabama • New York, New York • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 21, 2026, 10:24 PM EDT
Recruiting Phase 1 Interventional

UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy

NCT06047886
View directory record Official record
Conditions
AML, ALL, Lymphoid Malignancies, Myelodysplastic Syndromes, CML, Primary Myelofibrosis
Interventions
Infusion of CD34 selected hematopoietic stem cells
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
4 Weeks to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 21, 2026, 10:24 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy, Safety and Immunogenicity Study of GlaxoSmithKline(GSK) Biologicals' Candidate Malaria Vaccine 257049 in the Sporozoite Challenge Model in Healthy Malaria-naïve Adults

NCT01857869
View directory record Official record
Conditions
Malaria
Interventions
GSK257049 Dosage 1, GSK257049 Dosage 2, Sporozoite-infected mosquitoes challenge
Biological · Procedure
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Oct 21, 2026, 10:24 PM EDT
Completed Phase 2 Interventional

Randomized Amifostine For SCCHN

NCT00095927
View directory record Official record
Conditions
Chemotherapeutic Agent Toxicity, Head and Neck Cancer, Mucositis, Radiation Toxicity, Xerostomia
Interventions
Amifostine, Carboplatin, Paclitaxel, radiation
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
9
States / cities
Sanford, Maine • Boston, Massachusetts • Concord, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2017 · Synced Oct 21, 2026, 10:24 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors

NCT00187486
View directory record Official record
Conditions
Glioblastoma Multiforme, Gliosarcoma
Interventions
Tarceva, Temodar, Radiation Therapy
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Oct 21, 2026, 10:24 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir

NCT02511431
View directory record Official record
Conditions
Hepatitis D
Interventions
Lonafarnib, Ritonavir, Placebo
Drug · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 21, 2026, 10:24 PM EDT
Completed Phase 1 Interventional

Study of Safety and Immunogenicity of HIV Vaccines in Healthy Volunteers

NCT01989533
View directory record Official record
Conditions
Vaccine Response
Interventions
Ad4-mgag, Ad4-EnvC150, gp 120 Protein Boost
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 21, 2026, 10:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Combinatorial Therapy to Induce an HIV Remission

NCT04357821
View directory record Official record
Conditions
HIV/AIDS
Interventions
Combination Intervention
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 67 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 21, 2026, 10:24 PM EDT
Recruiting Phase 3 Interventional

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

NCT04852887
View directory record Official record
Conditions
Stage I Breast Cancer
Interventions
Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane), Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)
Other · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
50 Years to 70 Years
Enrollment
1,670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2041
U.S. locations
812
States / cities
Birmingham, Alabama • Mobile, Alabama • Kingman, Arizona + 553 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 21, 2026, 10:24 PM EDT
Recruiting Phase 2 Interventional

Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer

NCT07076485
View directory record Official record
Conditions
Breast Cancer
Interventions
Ultrahypofractionated Radiation, Moderately Hypofractionated Radiation
Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
768 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
5
States / cities
Loveland, Colorado • Jacksonville, Florida • Voorhees Township, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 21, 2026, 10:24 PM EDT
Completed Not applicable Interventional Results available

Stereotactic Body Radiation Therapy With Boost Using Urethral-Sparing Intensity-Modulated Radiation Therapy Planning in Treating Patients With Prostate Cancer

NCT02470897
View directory record Official record
Conditions
Stage I Prostate Adenocarcinoma, Stage II Prostate Adenocarcinoma
Interventions
Radiation Therapy Treatment Planning and Simulation, SBRT
Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Male only
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
3
States / cities
Rockford, Illinois • Johnson Creek, Wisconsin • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 10:24 PM EDT
Terminated Phase 3 Interventional

Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx, Hypopharynx, or Larynx

NCT00004227
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cetuximab, conventional surgery, radiation therapy
Biological · Procedure · Radiation
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
3
States / cities
Lakewood, New Jersey • Long Branch, New Jersey • Somerville, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 21, 2026, 10:24 PM EDT
Recruiting Not applicable Interventional

Deconstructing Voice Therapy: Towards Enhanced Communication Outcomes

NCT07176988
View directory record Official record
Conditions
Dysphonia, Primary Muscle Tension Dysphonia (MTD)
Interventions
Hierarchical method, Non Hierarchical method
Other
Lead sponsor
Emory University
Other
Eligibility
16 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 21, 2026, 10:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone

NCT01498718
View directory record Official record
Conditions
Influenza
Interventions
DNA vaccine, TIV
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
4
States / cities
Decatur, Georgia • St Louis, Missouri • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2016 · Synced Oct 21, 2026, 10:24 PM EDT
Recruiting Not applicable Interventional

Telehealth Cognitive Behavioral Therapy for Youth at Risk for Psychosis

NCT05968560
View directory record Official record
Conditions
Clinical High Risk for Psychosis (CHR)
Interventions
CBT Skills Group for CHR Youth, Individual CBT sessions, CBT Skills Group for Families
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
14 Years to 25 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 21, 2026, 10:24 PM EDT
Recruiting Phase 1 Interventional

SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer

NCT05412082
View directory record Official record
Conditions
Locally Advanced Rectal Cancer
Interventions
Intensity-modulated radiation therapy, 5-fluorouracil, Leucovorin, Oxaliplatin, Capecitabine, Accelerated Radiation Therapy, Irinotecan
Radiation · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 21, 2026, 10:24 PM EDT
Completed Phase 1 Interventional

A Study of the Safety and Effectiveness of an HIV Vaccine for HIV-Positive Patients Receiving Anti-HIV Drugs for at Least 2 Years

NCT00006509
View directory record Official record
Conditions
HIV Infections
Interventions
ALVAC(2)120(B,MN)GNP (vCP1452), gp160 MN/LAI-2
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Oct 21, 2026, 10:24 PM EDT
Completed Not applicable Interventional

Image-Guided Stereotactic Radiosurgery (SRS) Boost for HPV-Oropharyngeal Cancer

NCT02703493
View directory record Official record
Conditions
Cancer of the Oropharynx
Interventions
Stereotactic Radiosurgery
Radiation
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
1
States / cities
Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 21, 2026, 10:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

High-fat Meal Challenge in Pediatrics

NCT05230433
View directory record Official record
Conditions
Pediatric Obesity, Insulin Resistance
Interventions
High-fat Challenge
Dietary Supplement
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
8 Years to 17 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Oct 21, 2026, 10:24 PM EDT
Completed Phase 2 Interventional Results available

Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab

NCT04401995
View directory record Official record
Conditions
Melanoma
Interventions
Vidutolimod (CMP-001), Nivolumab, [18F]F-AraG PET/CT
Drug · Biological · Other
Lead sponsor
Diwakar Davar
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 21, 2026, 10:24 PM EDT